Marcela Mazo-Canola, MD
Hematology & Oncology · San Antonio, TXNPI 1801116462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $188,043 of the $256,562 with a category attached, or 73.3%. 27 manufacturers reported payments, led by Gilead at 59.0% of the total. 2025 is the largest year on record at $97,087, more than ten times the $745 reported in 2019. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $761.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$151K
- Stemline Therapeutics Inc.$49K
- AstraZeneca$47K
- Tersera Therapeutics LLC$3K
- Puma Biotechnology, Inc.$2K
- Seagen Inc.$1K
- plus $3K from 21 others
Across 14 payments — averaging $12,573 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Myriad Genetic Laboratories, Inc.$176K
What the payments were for
- Consulting fees$27,70311%
- Speaking & faculty fees$188,04373%
- Travel & lodging$32,91013%
- Food & beverage$7,5413%
- Education$670%
- Other$2990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 111 | $151,294 |
| Stemline Therapeutics Inc. | 54 | $49,386 |
| AstraZeneca | 36 | $47,221 |
| Tersera Therapeutics LLC | 7 | $2,746 |
| Puma Biotechnology, Inc. | 1 | $1,920 |
| Seagen Inc. | 3 | $1,015 |
| Pfizer | 36 | $524 |
| Novartis | 9 | $416 |
| Novo Nordisk | 14 | $351 |
| Myriad Genetic Laboratories, Inc. | 3 | $311 |
| Daiichi Sankyo Inc. | 6 | $226 |
| Eli Lilly | 2 | $207 |
| Radius Health, Inc. | 10 | $189 |
| Johnson & Johnson(2 entities) | 17 | $168 |
| Lilly USA, LLC | 8 | $141 |
| Incyte Corporation | 1 | $103 |
| Exelixis Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Merck | 2 | $41 |
| Bayer | 2 | $38 |
| Amgen | 2 | $38 |
| Medtronic | 2 | $35 |
| Genentech USA, Inc. | 1 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Dova Pharmaceuticals | 1 | $15 |
| Tempus AI, Inc | 1 | $15 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$256,562 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 38 | $494,425 |
| VerzenioAbemaciclib | 27 | $354,465 |
| IbrancePalbociclib | 15 | $269,409 |
| TruqapCapivasertib | 11 | $244,257 |
| Exemestane | 24 | $4,414 |
| Anastrozole | 171 | $2,667 |
| Ondansetron Hcl | 24 | $2,445 |
| Fentanyl | 17 | $1,823 |
| Letrozole | 67 | $1,428 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $1,233 |
| Prochlorperazine Maleate | 15 | $581 |
| Alendronate Sodium | 27 | $294 |
| Dexamethasone | 13 | $266 |
| Famotidine | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $416 | $494,42538 claims |
| Lilly USA, LLCVerzenio | $141 | $354,46527 claims |
| PfizerIbrance | $524 | $269,40915 claims |
| AstraZenecaTruqap | $47,221 | $244,25711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in San Antonio
- Timothy FenskeSan Antonio$626K
- Paul ShaughnessySan Antonio$470K
- Adolfo DiazSan Antonio$463K
- Francis GilesSan Antonio$436K
- John RenshawSan Antonio$430K
- Elizabeth Bowhay-CarnesSan Antonio$204K
- Nosha FarhadfarSan Antonio$117K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.